Patients & Visitors

Connective Tissue Diseases

F8

About us

Our connective tissue diseases (CTD) team offers a specialist clinical, research and laboratory service. The team is led by two consultant rheumatologists and includes a consultant nurse, with specialist registrars and research fellows attached on a rotational basis. The service receives local, national and international referrals.

Connective tissue diseases cover a wide range of autoimmune diseases including:

  • Systemic Lupus Erythematosus (SLE)
  • Antiphospholipid Syndrome
  • Raynaud's Phenomenon
  • Systemic Sclerosis
  • Sjogren's Syndrome
  • Snflammatory Myopathies, eg. polymyositis, dermatomyositis
  • Primary Vasculitides, eg. Polyangiitis with granuloma, churg strauss, polyarteritis nodosa
  • Mixed Connective Tissue Disease (MCTD)
  • Undifferentiated Connective Tissue Disease (UCTD)
  • Behcet's Disease

A collaborative and multidisciplinary approach to the management of these conditions is essential.

Why choose us?

Our CTD service offers a multi-disciplinary approach to diagnosis, treatment and management. Our specialist therapy service supports both inpatients and outpatients. Dedicated clinics for patients with CTDs are consultant-led, with a nurse specialist clinic running at the same time for education, support, advice and counselling.

We work with pulmonary and dermatology colleagues across the health community to provide combined medical specialist clinics. These include a specialist pulmonary hypertension clinic, a monthly pulmonary/rheumatology clinic, a monthly dermatology/rheumatology clinic and a two monthly pulmonary hypertension clinic.

We are a training hospital and have rotating registrars and visiting fellows in rheumatology both local and international. We provide training for others through national study days and CTD meetings.

We form part of a national network of expertise for CTD. Professor Neil McHugh, head of the CTD team, is an active member of the UK Systemic Sclerosis Study Group, the British Isles Lupus Assessment Group and the European Myositis Consortium.

back to top